Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA) - PubMed (original) (raw)
Guideline
. 2000 Feb;14(2):267-72, 277-8, 280 passim.
- PMID: 10736812
Guideline
Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA)
No authors listed. Oncology (Williston Park). 2000 Feb.
Abstract
Prostate cancer is one of the most common forms of noncutaneous cancer in men in the United States. Despite its prevalence, the natural history of this disease is remarkably heterogeneous. In many patients, the cancer progresses slowly, resulting in moderately or poorly differentiated tumors that remain localized to the prostate gland. Although potentially life-threatening, such cancers are often curable. In other patients, however, tumor growth is rapid and can spread beyond the confines of the prostate. In such cases, the cancer is not curable, and long-term survival is considerably diminished. Strategies for managing prostate cancer have therefore been aimed at early detection and local treatment of the cancer. Prostate-specific antigen (PSA) is a tumor marker currently used for early detection of prostate cancer. Measurement of serum PSA levels has significant clinical application in other areas of prostate disease management. The purpose of this report is to provide current information on the use of PSA testing for: (1) the evaluation of men at risk for prostate cancer, (2) assistance in pretreatment staging, and (3) the posttreatment monitoring and management of men with this disease. The following summary is based on a review of the literature and the expert opinions of a multispecialty panel convened by the American Urological Association (AUA). It is intended to serve as a resource for urologists and primary care physicians.
Similar articles
- Prostate specific antigen best practice statement: 2009 update.
Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P. Greene KL, et al. J Urol. 2009 Nov;182(5):2232-41. doi: 10.1016/j.juro.2009.07.093. Epub 2009 Sep 24. J Urol. 2009. PMID: 19781717 - Prostate specific antigen best practice statement: 2009 update.
Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P; American Urological Association. Greene KL, et al. J Urol. 2013 Jan;189(1 Suppl):S2-S11. doi: 10.1016/j.juro.2012.11.014. J Urol. 2013. PMID: 23234625 - Prostate cancer: diagnostic and therapeutic strategies with emphasis on the role of PSA.
Khauli RB. Khauli RB. J Med Liban. 2005 Apr-Jun;53(2):95-102. J Med Liban. 2005. PMID: 16604995 Review. - Prostate-specific antigen kinetics in localized and advanced prostate cancer.
Fitzpatrick JM, Banu E, Oudard S. Fitzpatrick JM, et al. BJU Int. 2009 Mar;103(5):578-87. doi: 10.1111/j.1464-410X.2009.08345.x. Epub 2009 Feb 6. BJU Int. 2009. PMID: 19210674 Review.
Cited by
- Quantification of Urinary Exosomal Prostate-Specific Antigen for the Diagnosis of Prostate Cancer Using Clinical Laboratory-Based Techniques: Protocol for a Case-Control Study.
Li G, Tholance Y, Mallouk N, Waeckel L, Flandrin P, Bali B, Badet L, Cornillon P. Li G, et al. JMIR Res Protoc. 2024 Sep 11;13:e63551. doi: 10.2196/63551. JMIR Res Protoc. 2024. PMID: 39024018 Free PMC article. - T2-Weighted MRI Radiomic Features Predict Prostate Cancer Presence and Eventual Biochemical Recurrence.
Duenweg SR, Bobholz SA, Barrett MJ, Lowman AK, Winiarz A, Nath B, Stebbins M, Bukowy J, Iczkowski KA, Jacobsohn KM, Vincent-Sheldon S, LaViolette PS. Duenweg SR, et al. Cancers (Basel). 2023 Sep 6;15(18):4437. doi: 10.3390/cancers15184437. Cancers (Basel). 2023. PMID: 37760407 Free PMC article. - Urine spermine and multiparametric magnetic resonance imaging for prediction of prostate cancer in Japanese men.
Isotani S, Ka-Fung Chiu P, Ashizawa T, Fung YH, Ieda T, China T, Kawano H, Shimizu F, Nagata M, Nakagawa Y, Muto S, Wong KL, Ng CF, Horie S. Isotani S, et al. Prostate Int. 2023 Sep;11(3):180-185. doi: 10.1016/j.prnil.2023.07.003. Epub 2023 Jul 20. Prostate Int. 2023. PMID: 37745906 Free PMC article. - Diagnostic accuracy of prostate-specific antigen below 4 ng/mL as a cutoff for diagnosing prostate cancer in a hospital setting: A systematic review and meta-analysis.
Jin Y, Jung JH, Han WK, Hwang EC, Nho Y, Lee N, Yun JE, Lee KS, Lee SH, Lee H, Yu SY. Jin Y, et al. Investig Clin Urol. 2022 May;63(3):251-261. doi: 10.4111/icu.20210429. Investig Clin Urol. 2022. PMID: 35534215 Free PMC article. - Prostate cancer screening: A survey of medical students' knowledge in Lome, Togo, and associated determinants in a resource-limited African context.
Darré T, Djiwa T, Kpatcha TM, Sidibé A, Sewa E, Botcho G, Padja E, Napo-Koura G. Darré T, et al. SAGE Open Med. 2021 Jul 17;9:20503121211032812. doi: 10.1177/20503121211032812. eCollection 2021. SAGE Open Med. 2021. PMID: 34349998 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous